Moderna, Inc.

As of June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs carries a market capitalization of 26.86B, placing it among publicly traded companies globally. Its enterprise value stands at 23.01B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs has 7.00B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 11.99, and the price-to-book ratio stands at 3.97.

These figures are as of June 30, 2026. The EV/Sales ratio of 10.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 23.01B versus a market cap of 26.86B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs maintains a current ratio of 2.29, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.04, indicating elevated leverage, while an interest coverage ratio of -73.31 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs posted a negative return on equity (ROE) of -39.00, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -27.43, reflecting losses generated across the asset base. The company generates approximately 444,221.11 in revenue per employee across its workforce of 4,975.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.57 indicates how many times Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs recorded 64.00M in income tax expense. The company reported a pretax loss of -3.09B and -3.15B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs's stock has gained approximately 709.96% over the past 52 weeks. The 50-day moving average sits at 9.18, while the 200-day moving average is 4.41.

Over the twelve months ended June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs generated 2.21B in revenue and converted that into -3.15B in net income, yielding earnings per share of -0.46. EBITDA reached -3.08B, while operating income came in at -3.32B.

As of June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs holds 5.14B in cash and equivalents against 1.29B in total debt, resulting in a net debt position of -1.13B. Total book value stands at 6.76B, with working capital of 3.28B providing operational flexibility.

Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs produced -1.07B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -171.00M in capital expenditures, free cash flow totaled -1.24B - equivalent to -0.18 per share.

Over the twelve months ended June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs posted a gross margin of 22.76, reflecting its pricing power and cost economics. The operating margin of -150.23 and net profit margin of -142.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.27, meaning Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs has an Altman Z-Score of 4.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.